ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 186 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $524,790 | +1.5% | 3,848 | -30.3% | 0.01% | -9.1% |
Q3 2023 | $516,799 | +3.1% | 5,519 | -1.7% | 0.01% | +10.0% |
Q2 2023 | $501,317 | -20.6% | 5,617 | -4.6% | 0.01% | -23.1% |
Q1 2023 | $631,204 | -15.8% | 5,887 | -4.1% | 0.01% | -13.3% |
Q4 2022 | $750,000 | -54.1% | 6,141 | -61.2% | 0.02% | -55.9% |
Q3 2022 | $1,633,000 | +4.9% | 15,816 | -5.6% | 0.03% | +13.3% |
Q2 2022 | $1,557,000 | -20.9% | 16,749 | -0.1% | 0.03% | 0.0% |
Q1 2022 | $1,968,000 | -10.0% | 16,771 | +3.2% | 0.03% | -3.2% |
Q4 2021 | $2,186,000 | -7.4% | 16,251 | +9.7% | 0.03% | -13.9% |
Q3 2021 | $2,360,000 | +19.4% | 14,808 | -1.4% | 0.04% | +24.1% |
Q2 2021 | $1,976,000 | +11.3% | 15,020 | +9.0% | 0.03% | +3.6% |
Q1 2021 | $1,776,000 | +25.1% | 13,780 | +61.9% | 0.03% | +21.7% |
Q4 2020 | $1,420,000 | +100.3% | 8,513 | +85.2% | 0.02% | +76.9% |
Q3 2020 | $709,000 | +18.8% | 4,597 | +13.9% | 0.01% | +8.3% |
Q2 2020 | $597,000 | +295.4% | 4,037 | +200.4% | 0.01% | +200.0% |
Q1 2020 | $151,000 | – | 1,344 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |